# Expert Documents Report

## Document Type Distribution in sources_google

| Document Type | Count | Percentage |
|--------------|-------|------------|
| low level folder | 184 | 22% |
| high level folder | 126 | 15.1% |
| video mpeg | 116 | 13.9% |
| Presentation Announcement | 94 | 11.2% |
| research article | 91 | 10.9% |
| Chat Log | 50 | 6% |
| dicussion transcript | 27 | 3.2% |
| review article | 23 | 2.7% |
| email correspondence | 21 | 2.5% |
| journal article | 15 | 1.8% |
| presentation transcript | 12 | 1.4% |
| professional biography | 9 | 1.1% |
| report | 8 | 1% |
| web news article | 7 | 0.8% |
| curriculum vitae | 6 | 0.7% |
| url blog post | 6 | 0.7% |
| website | 5 | 0.6% |
| Unknown | 4 | 0.5% |
| essay | 4 | 0.5% |
| Code Documentation Markdown | 4 | 0.5% |
| letter | 3 | 0.4% |
| editorial | 3 | 0.4% |
| unknown document type | 2 | 0.2% |
| new work summary | 2 | 0.2% |
| magazine article | 2 | 0.2% |
| word document | 2 | 0.2% |
| book | 2 | 0.2% |
| mp4 video | 1 | 0.1% |
| letter to the editor | 1 | 0.1% |
| correction | 1 | 0.1% |
| powerpoint document | 1 | 0.1% |
| root folder | 1 | 0.1% |
| science meeting discussion | 1 | 0.1% |
| pdf document | 1 | 0.1% |
| preprint | 1 | 0.1% |
| Deployment Script | 1 | 0.1% |

## Unclassified MIME Types

| MIME Type | Count | Percentage of Unclassified |
|-----------|-------|-------------------------|

## Sources Google Summary

| Status | Count | Percentage |
|--------|-------|------------|
| Total sources_google records (not deleted) | 837 | 100% |
| Total folders | 180 | 21.5% |
| Total files (not folders) | 657 | 78.5% |

## Document Type Status

| Status | Count | Percentage of Total |
|--------|-------|--------------------|
| Sources with document type | 837 | 100% |
| Sources without document type | 0 | 0% |

## Expert Documents Status

| Status | Count | Percentage of Files |
|--------|-------|--------------------|
| Sources with expert documents | 536 | 81.6% |
| Sources with document type but no expert documents | 301 | 45.8% |
| Files with no expert documents | 121 | 18.4% |

## MIME Type Breakdown

| MIME Type | Total Files | With Document Type | Without Document Type | % Classified |
|-----------|-------------|-------------------|----------------------|-------------|
| application/vnd.openxmlformats-officedocument.wordprocessingml.document | 191 | 191 | 0 | 100% |
| application/vnd.google-apps.folder | 180 | 180 | 0 | 100% |
| application/pdf | 151 | 151 | 0 | 100% |
| video/mp4 | 116 | 116 | 0 | 100% |
| audio/x-m4a | 92 | 92 | 0 | 100% |
| text/plain | 64 | 64 | 0 | 100% |
| application/vnd.openxmlformats-officedocument.presentationml.presentation | 25 | 25 | 0 | 100% |
| application/vnd.google-apps.document | 4 | 4 | 0 | 100% |
| image/jpeg | 3 | 3 | 0 | 100% |
| audio/x-mpegurl | 2 | 2 | 0 | 100% |
| text/html | 2 | 2 | 0 | 100% |
| application/msword | 2 | 2 | 0 | 100% |
| application/vnd.ms-powerpoint | 2 | 2 | 0 | 100% |
| audio/mpeg | 1 | 1 | 0 | 100% |
| application/octet-stream | 1 | 1 | 0 | 100% |
| video/mpeg | 1 | 1 | 0 | 100% |

## Expert Documents by Document Type

| Document Type | Count | Percentage of Expert Docs |
|--------------|-------|-------------------------|
| video mpeg | 112 | 20.9% |
| Presentation Announcement | 94 | 17.5% |
| research article | 91 | 17% |
| Chat Log | 50 | 9.3% |
| Unknown | 30 | 5.6% |
| review article | 23 | 4.3% |
| email correspondence | 21 | 3.9% |
| journal article | 15 | 2.8% |
| presentation transcript | 12 | 2.2% |
| dicussion transcript | 12 | 2.2% |
| professional biography | 9 | 1.7% |
| report | 8 | 1.5% |
| web news article | 7 | 1.3% |
| curriculum vitae | 6 | 1.1% |
| url blog post | 6 | 1.1% |
| website | 5 | 0.9% |
| Code Documentation Markdown | 4 | 0.7% |
| essay | 4 | 0.7% |
| letter | 3 | 0.6% |
| editorial | 3 | 0.6% |
| low level folder | 2 | 0.4% |
| magazine article | 2 | 0.4% |
| book | 2 | 0.4% |
| new work summary | 2 | 0.4% |
| unknown document type | 2 | 0.4% |
| word document | 2 | 0.4% |
| preprint | 1 | 0.2% |
| high level folder | 1 | 0.2% |
| correction | 1 | 0.2% |
| powerpoint document | 1 | 0.2% |
| mp4 video | 1 | 0.2% |
| letter to the editor | 1 | 0.2% |
| pdf document | 1 | 0.2% |
| Deployment Script | 1 | 0.2% |
| science meeting discussion | 1 | 0.2% |

## Sample Expert Documents

### 1. Naviaux.Mitochondria.chronic Disease.mp4 (video mpeg)

- ID: `b94942bd-e6da-49b2-acb4-3d9e001c2f2a`
- MIME Type: video/mp4
- Source ID: `d941e474-42bd-4780-91cd-b6a9894c9317`

**Raw Content Preview:**

> you know, anything last more than six months, I consider chronic. Right.

**Processed Content Preview:**

> # Summary: Advances in Targeted Immunotherapy for Metastatic Melanoma

## Background
The presentation opened with epidemiological data showing the rising incidence of melanoma globally, with approximately 324,000 new cases and 57,000 deaths annually. Despite representing only 5% of skin cancers, melanoma accounts for over 75% of skin cancer-related deaths.

---

### 2. Ron Gharbo Summary.1.27.21.docx (report)

- ID: `5c8f8809-c906-4ab3-a2a3-584ace575f9d`
- MIME Type: application/vnd.openxmlformats-officedocument.wordprocessingml.document
- Source ID: `3e85f3df-b8f2-4cba-9609-cbe43a858fd1`

**Raw Content Preview:**

> Ron Gharbo Summary1.27.21A pragmatic biopsychosocial objective starting point for most situations because we are all energy allocating, acquiring, restoration utilization organisms continually adapting to external and internal changes. 1.

**Processed Content Preview:**

> {"title":"Ron Gharbo Summary.1.27.21.docx","source":{"drive_id":"1Rg_QOhBB4gwYTmFgYBGRG0Ust_6dTV_j","mime_type":"application/vnd.openxmlformats-officedocument.wordprocessingml.document"},"content":"Ron Gharbo Summary1.27.21A pragmatic biopsychosocial objective starting point for most situations because we are all energy allocating, acquiring, restoration utilization organisms continually adapting to external and internal changes. 1.

---

### 3. Wager.7.15.20.mp4 (video mpeg)

- ID: `556d8749-f59e-4704-a388-a46a7ee88d07`
- MIME Type: video/mp4
- Source ID: `96bca436-b517-4374-ba55-bed14e6f775f`

**Raw Content Preview:**

> So that you have done a minute and else looking at the neocortex with the midbrain and just leaking these things together, which is why we're actually here. So do you have your slide deck up by chance? I do, yes.

**Processed Content Preview:**

> # Summary: Mitochondrial Dysfunction in Metabolic Disorders

## Key Concepts Presented
The presentation provided a comprehensive overview of how mitochondrial dysfunction contributes to various metabolic disorders, emphasizing the critical role of mitochondria as cellular powerhouses. ## Pathophysiological Mechanisms
- Detailed explanation of electron transport chain defects and their consequences on ATP production
- Analysis of reactive oxygen species (ROS) accumulation causing oxidative stress and cellular damage
- Discussion of mtDNA mutations that impair mitochondrial protein synthesis and function
- Exploration of altered calcium homeostasis disrupting cellular signaling pathways

## Clinical Manifestations
- Multi-system involvement with particular emphasis on high-energy demanding tissues (brain, muscle, heart)
- Presentation of case studies demonstrating phenotypic variability
- Age-dependent symptom progression and threshold effects
- Diagnostic challenges due to overlapping clinical presentations

## Diagnostic Approaches
- Comprehensive metabolic panels showing characteristic biomarkers (lactate, pyruvate ratios)
- Muscle biopsy findings including ragged red fibers and COX-negative fibers
- Advanced imaging techniques revealing metabolic signatures
- Next-generation sequencing for genetic diagnosis

## Therapeutic Strategies
- Current mitochondrial-targeted therapies including coenzyme Q10, riboflavin, and L-carnitine
- Emerging approaches using antioxidants and metabolic modifiers
- Precision medicine approaches based on specific mitochondrial defects
- Lifestyle modifications including exercise protocols and dietary interventions

## Research Frontiers
- Mitochondrial replacement therapies and ethical considerations
- CRISPR-based approaches for mtDNA editing
- Metabolic reprogramming strategies
- Biomarker development for early detection and monitoring.

---

### 4. Lustig Announcement.docx (Presentation Announcement)

- ID: `9096b8cb-bce0-45b3-8ee5-cddefc313bbf`
- MIME Type: application/vnd.openxmlformats-officedocument.wordprocessingml.document
- Source ID: `96e1636d-8c7c-44e8-a2ca-b894fb1b1ba8`

**Raw Content Preview:**

> Lustig Announcement 1.8.25 Hi everyone, The next Dynamic Healing Study Group meeting will be on Wednesday, January 8th, at 5 pm PT. Here is the Zoom link: https://us02web.zoom.us/j/98327644404 Dr.

**Processed Content Preview:**

> {"research_summary":"Dr. Lustig's research focuses on the intersection of neuroscience, metabolism, and public health, with particular emphasis on the role of the amygdala in systemic health disorders.

---

### 5. Summary of Brenda Stockdale_Bernie Seigel (presentation transcript)

- ID: `70bf68ef-1975-4f1d-a0e7-798f24313109`
- MIME Type: application/vnd.google-apps.document
- Source ID: `a8b4a68f-0d0f-4d87-82e3-7d4f0a181d94`

**Raw Content Preview:**

> Summary of Brenda Stockdale/ Bernie Seigel’s  presentation of what are the traits of people who survive  terminal cancer 
2.19.25 
This meeting is a major paradigm shift. Exceptional cancer survivors don’t just magically  heal.

**Processed Content Preview:**

> {"key_topics":["Exceptional cancer survival traits","Self-induced healing","Mind-body connection in recovery","The 3 C's: Control, Commitment, and Challenge","Role of hope and positive narratives","Ethical considerations in treatment approaches","Integrated model of deep healing"],"document_type":"presentation transcript","target_audience":"Healthcare professionals, cancer patients, psychologists, and individuals interested in integrative medicine approaches to healing","unique_insights":["People-pleasing behavior (putting others' needs before one's own) is linked to poorer health outcomes in cancer patients","The concept of 'therapeutic deception' - framing diagnoses to foster hope - can measurably improve health outcomes despite ethical concerns","Specific psychological traits can be intentionally developed to enhance physiological healing processes"],"document_summary":"This document summarizes a presentation by Brenda Stockdale and Bernie Seigel on the traits of exceptional cancer survivors. The presentation, dated February 19, 2025, introduces the concept of 'self-induced healing' and challenges traditional biomedical models by proposing that recovery from cancer is significantly influenced by mindset, emotions, and behavior rather than solely by clinical interventions.\n\nThe summary outlines seven key sections of the presentation, beginning with an introduction to a new healing paradigm that frames stress and illness as opportunities for transformative growth.

---

### 6. Summary of Brenda Stockdale_Bernie Seigel (presentation transcript)

- ID: `12f40d61-5c7b-45e7-9c79-7fdb180e18c9`
- MIME Type: application/vnd.google-apps.document
- Source ID: `3414c255-6163-4070-950e-c573502047b1`

**Raw Content Preview:**

> Summary of Brenda Stockdale/ Bernie Seigel’s  presentation of what are the traits of people who survive  terminal cancer 
2.19.25 
This meeting is a major paradigm shift. Exceptional cancer survivors don’t just magically  heal.

**Processed Content Preview:**

> {"document_type":"presentation transcript","document_summary":"This document summarizes a presentation by Brenda Stockdale and Bernie Seigel focused on the traits and behaviors of exceptional cancer survivors. The presentation challenges traditional medical models by emphasizing how mindset, emotions, and behavior significantly impact recovery and longevity.

---

### 7. Global developments in social prescribing_Morse_2022.pdf (research article)

- ID: `d9ace790-346e-4db0-a28d-0f77b584c07d`
- MIME Type: application/pdf
- Source ID: `b3fcdb12-25c7-46dc-88c8-f0fddc1dedac`

**Raw Content Preview:**

> Not available

**Processed Content Preview:**

> {"key_topics":["Social prescribing implementation across 17 countries","Addressing social determinants of health through healthcare systems","Cross-sector collaboration between health, social, and community services","Workforce models for social prescribing delivery","Financing approaches for sustainable social prescribing programs"],"limitations":"The article acknowledges that evidence for social prescribing effectiveness is still emerging, with limited robust evaluations across different contexts. Implementation approaches vary widely between countries, making standardized assessment challenging.

---

### 8. Unknown file (Unknown)

- ID: `199a8efb-5589-4170-a686-62f34315ed92`
- MIME Type: Not specified
- Source ID: `235fd3ac-2727-405d-96a4-809acb927374`

**Raw Content Preview:**

> Thank you. Take you to save my life.

**Processed Content Preview:**

> {"transcription":{"model":"base","audio_file":"/Users/raybunnage/Documents/github/dhg-mono/file_types/m4a/Kovacic.Porges.106.21.m4a","word_count":9730,"processing_time_seconds":102.661,"transcription_timestamp":"2025-04-06T22:00:51.698Z"},"audio_metadata":{"file_path":"/Users/raybunnage/Documents/github/dhg-mono/file_types/m4a/Kovacic.Porges.106.21.m4a","source_file":"Kovacic.Porges.106.21.m4a","file_size_bytes":57140343},"processing_stats":{"model_type":"base","processing_date":"2025-04-06T22:00:51.697Z","words_per_minute":5687,"audio_duration_seconds":0,"transcription_time_seconds":102.661},"summary_complete":false,"transcription_complete":true}.

---

### 9. Lustig.Amygdala.1.8.25.mp4 (video mpeg)

- ID: `846246b7-e992-41ba-80c8-50736bd30b9b`
- MIME Type: video/mp4
- Source ID: `f248b090-3e99-4eef-aa7c-62e7284bd88f`

**Raw Content Preview:**

> For as many zoom meetings as I do, people might, people I work with, make fun of me in my lack of technical skills here. I'm, I think it's a genetic defect.

**Processed Content Preview:**

> # Summary: New Approaches to Treating Chronic Lower Back Pain

## Introduction
The presentation discussed the evolving understanding of chronic lower back pain (CLBP) as a complex, multifactorial condition requiring individualized, multimodal treatment approaches rather than a one-size-fits-all methodology. ## Epidemiology and Economic Impact
- CLBP affects approximately 20% of adults globally
- Leading cause of disability worldwide
- Annual economic burden exceeds $100 billion in the US alone through direct medical costs and lost productivity
- Disproportionately affects working-age adults (30-50 years)

## Pathophysiology Updates
The presentation highlighted recent research revealing:
- Central sensitization mechanisms in chronic pain maintenance
- Neuroplastic changes in pain processing pathways
- Inflammatory mediators' role in perpetuating pain cycles
- Genetic factors influencing pain perception and chronicity

## Diagnostic Advancements
- Enhanced MRI techniques including functional MRI to visualize neural pain pathways
- Quantitative sensory testing to assess pain processing abnormalities
- Biomarker identification for pain subtypes
- Machine learning algorithms to predict treatment response

## Multimodal Treatment Framework
The presentation emphasized an integrated approach including:

### Pharmacological Innovations
- Targeted anti-cytokine therapies
- Novel sodium channel blockers
- Monoclonal antibodies for specific pain pathways
- Personalized medication protocols based on genetic testing

### Interventional Procedures
- Ultrasound-guided precision injections
- Minimally invasive endoscopic techniques
- Pulsed radiofrequency neuromodulation
- Advanced spinal cord stimulation with closed-loop systems

### Physical Rehabilitation
- Motor control retraining protocols
- Graded exposure therapy for movement-related fear
- Directional preference-based exercise programs
- Virtual reality-assisted rehabilitation

### Psychological Approaches
- Acceptance and Commitment Therapy (ACT) adaptations for pain
- Pain neuroscience education programs
- Mindfulness-based stress reduction
- Cognitive Behavioral Therapy with pain-specific modules

## Emerging Technologies
- Wearable devices for real-time movement analysis and feedback
- Smartphone applications for pain self-management
- Telemedicine platforms for remote monitoring and intervention
- AI-driven decision support systems for treatment selection

## Clinical Implementation
The presentation concluded with practical recommendations for:
- Risk stratification tools to match patients with appropriate treatments
- Interdisciplinary team structures for comprehensive care
- Outcome measurement frameworks to track progress
- Cost-effectiveness considerations in treatment selection

## Conclusion
The presentation emphasized the shift toward precision medicine in CLBP management, with treatments tailored to specific pain mechanisms and patient characteristics rather than generic approaches based solely on symptom presentation..

---

### 10. Wager.Intro.Networks.Intro.6.17.20.mp4 (video mpeg)

- ID: `2c7e221f-7c59-4cb5-bdea-da3cbaa24f62`
- MIME Type: video/mp4
- Source ID: `f5c33cbb-c49e-4d70-9333-9f6f56ee722a`

**Raw Content Preview:**

> last time when they look sort of, you know, from a different direction top down, functional MRI stuff. The play, the story that unfolds for me sort of in front of me in the clinic that I feel like I see in my mind doesn't always add up on functional MRI.

**Processed Content Preview:**

> # Summary: Recent Breakthroughs in Alzheimer's Disease Research

## Introduction
The presentation highlighted significant advances in understanding the pathophysiology, diagnosis, and treatment of Alzheimer's disease (AD), emphasizing how these developments are reshaping clinical approaches. ## Key Pathophysiological Insights
- **Amyloid and Tau Relationship**: New evidence confirms the "amyloid cascade hypothesis" with refined understanding of how amyloid-beta accumulation triggers tau pathology through specific molecular pathways
- **Neuroinflammatory Mechanisms**: Research revealed the critical role of microglial activation in disease progression, identifying TREM2 and CD33 as key regulatory proteins
- **Vascular Contributions**: Studies demonstrated that cerebrovascular dysfunction accelerates cognitive decline, suggesting integrated treatment approaches

## Diagnostic Advancements
- **Blood-Based Biomarkers**: Plasma p-tau217 and p-tau181 demonstrated 94% accuracy in detecting AD pathology, potentially reducing reliance on costly PET imaging
- **Digital Biomarkers**: AI-powered speech and movement analysis tools showed promise for early detection, with 88% sensitivity in identifying pre-symptomatic cases
- **Enhanced Neuroimaging**: New PET tracers specifically targeting tau tangles enable visualization of disease progression patterns

## Therapeutic Breakthroughs
- **Anti-Amyloid Monoclonal Antibodies**: Lecanemab and donanemab showed significant amyloid plaque reduction (70-80%) with modest cognitive benefits in early-stage disease
- **Tau-Targeting Approaches**: Phase II trials of tau aggregation inhibitors demonstrated 28% reduction in disease progression
- **Combination Therapies**: Multi-target approaches addressing both pathology and symptoms showed superior outcomes compared to monotherapies

## Emerging Research Directions
- **Gut-Brain Axis**: Microbiome alterations correlate with AD progression, opening avenues for dietary interventions
- **Lifestyle Interventions**: The FINGER study demonstrated that multi-domain lifestyle modifications reduced cognitive decline by up to 25%
- **Precision Medicine**: Genetic profiling enables tailored treatment approaches based on individual risk factors

## Clinical Implications
The presentation concluded that these advances are transforming AD from a hopeless diagnosis to a manageable condition, emphasizing the importance of early intervention and comprehensive care approaches..

---

